Tourmaline Bio, Inc. (TRML)
After hours:
| Previous Close | 15.50 |
| Open | 15.32 |
| Bid | 15.75 x 400 |
| Ask | 15.93 x 100 |
| Day's Range | 15.14 - 15.83 |
| 52 Week Range | 9.18 - 48.31 |
| Volume | |
| Avg. Volume | 432,262 |
| Market Cap | 405.984M |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | May 13, 2024 - May 17, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 58.33 |
GlobeNewswireAvalo Therapeutics Appoints Biotech Leaders to Board of Directors
Appointments include industry veterans Aaron Kantoff, Jonathan Goldman, and Samantha Truex as Independent DirectorsBoard of Director appointments in conjunction with Avalo’s recent acquisition of AVTX-009, an anti-IL-1β mAb, and up to $185 million private placement financing WAYNE, Pa. and ROCKVILLE, Md., April 02, 2024 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX) today announced the addition of multiple biotech leaders to its Board of Directors. The Avalo Board brings together a
GlobeNewswireTourmaline Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights
– Initiated pivotal spiriTED Phase 2b trial in Thyroid Eye Disease (TED) in 2023 and expanded TED clinical development plan, including accelerating the planned initiation of a pivotal Phase 3 trial into 2024 – – Reached alignment with the U.S. FDA on the clinical development program in Atherosclerotic Cardiovascular Disease (ASCVD) in 2023 and received clearance for Investigational New Drug application (IND) in March 2024 – – Completed reverse merger with Talaris Therapeutics in October 2023, in
Simply Wall St.Bullish Tourmaline Bio Insiders Loaded Up On US$643.3k Of Stock
Generally, when a single insider buys stock, it is usually not a big deal. However, when several insiders are buying...
